Innogen’s Suzhou Facility Clears Brazilian Regulatory Hurdle

The certification serves as a validation of the company's quality control systems, effectively streamlining the path for Efsubaglutide alfa to enter emerging regions that prioritize PIC/S-aligned compliance. For Innogen, Brazil represents a high-priority target given the country's significant patient population; roughly 16.6 million adults there live with diabetes, while obesity rates among the adult population exceed 26 percent.

Efsubaglutide alfa, a human-derived, ultra-long-acting GLP-1 receptor agonist, has already established a footprint in Mainland China and Macau. Clinical data from the SUPER series trials showed a 2.2 percent reduction in HbA1c levels for treatment-naïve patients over 24 weeks. Beyond diabetes, the company is actively testing the drug’s weight management potential, with ongoing phase II trials in Australia and recent progress in adolescent obesity research. CEO Wang Qinghua noted that the ANVISA approval functions as a gateway to broader commercialization, allowing the firm to leverage its proprietary intellectual property across Latin America and Southeast Asia.